The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.
Noro
Rintaro
R
Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo, Japan.
Miyanaga
Akihiko
A
Shimokawa
Tsuneo
T
Kuribayashi
Hidehiko
H
Mizutani
Hideaki
H
Minegishi
Yuji
Y
Okano
Tetsuya
T
Seike
Masahiro
M
Soeno
Chie
C
Kataoka
Kiyoko
K
Matsuda
Kuniko
K
Yoshimura
Akinobu
A
Gemma
Akihiko
A
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004354:Drug Screening Assays, Antitumor; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured; D000077337:Vorinostat
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C012589:trichostatin A; D000077337:Vorinostat